Arvinas Future Growth
Future criteria checks 2/6
Arvinas is forecast to grow earnings and revenue by 27.1% and 35.6% per annum respectively. EPS is expected to grow by 31.5% per annum. Return on equity is forecast to be -49% in 3 years.
Key information
27.1%
Earnings growth rate
31.5%
EPS growth rate
Pharmaceuticals earnings growth | 20.9% |
Revenue growth rate | 35.6% |
Future return on equity | -49.0% |
Analyst coverage | Good |
Last updated | 12 Apr 2024 |
Recent future growth updates
Recent updates
Arvinas: Behind The Huge Rally
Mar 03What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You
Feb 25News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts
Aug 13There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price
May 05Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)
Feb 24Arvinas initiated Overweight at Barclays on attractive therapeutic platform
Sep 09Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment
Aug 19Arvinas: Still Holding, Just Not Buying More
May 23Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma
Feb 07Arvinas: 2022 Is Full Of Catalysts For This Protein Degrader Pioneer
Nov 19Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 291 | -319 | -314 | -260 | 14 |
12/31/2025 | 217 | -336 | -330 | -285 | 18 |
12/31/2024 | 161 | -327 | -264 | -338 | 17 |
12/31/2023 | 79 | -367 | -351 | -348 | N/A |
9/30/2023 | 159 | -295 | -340 | -336 | N/A |
6/30/2023 | 158 | -298 | -323 | -318 | N/A |
3/31/2023 | 137 | -301 | -313 | -308 | N/A |
12/31/2022 | 131 | -282 | -280 | -273 | N/A |
9/30/2022 | 127 | -253 | -246 | -238 | N/A |
6/30/2022 | 103 | -233 | 503 | 510 | N/A |
3/31/2022 | 75 | -213 | 536 | 541 | N/A |
12/31/2021 | 54 | -191 | 555 | 559 | N/A |
9/30/2021 | 23 | -180 | 562 | 566 | N/A |
6/30/2021 | 21 | -164 | -142 | -138 | N/A |
3/31/2021 | 21 | -139 | -118 | -112 | N/A |
12/31/2020 | 26 | -119 | -96 | -90 | N/A |
9/30/2020 | 24 | -99 | -83 | -77 | N/A |
6/30/2020 | 47 | -86 | -59 | -53 | N/A |
3/31/2020 | 45 | -78 | -52 | -45 | N/A |
12/31/2019 | 43 | -70 | -47 | -41 | N/A |
9/30/2019 | 42 | -65 | -42 | -37 | N/A |
6/30/2019 | 15 | -173 | -54 | -50 | N/A |
3/31/2019 | 14 | -179 | -51 | -48 | N/A |
12/31/2018 | 14 | -240 | -19 | -16 | N/A |
9/30/2018 | 13 | -233 | 22 | 24 | N/A |
6/30/2018 | 12 | -114 | 26 | 28 | N/A |
3/31/2018 | 10 | -98 | 30 | 31 | N/A |
12/31/2017 | 8 | -29 | 4 | 5 | N/A |
12/31/2016 | 7 | -12 | N/A | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARVN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ARVN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ARVN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ARVN's revenue (35.6% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: ARVN's revenue (35.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ARVN is forecast to be unprofitable in 3 years.